GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (GREY:CPTCF) » Definitions » Buyback Yield %

CPTCF (Cytophage Technologies) Buyback Yield % : -18.33 (As of May. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Cytophage Technologies's current buyback yield was -18.33%.


Cytophage Technologies Buyback Yield % Historical Data

The historical data trend for Cytophage Technologies's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Buyback Yield % Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23
Buyback Yield %
- - -

Cytophage Technologies Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -9.04 -10.73 -14.66

Competitive Comparison of Cytophage Technologies's Buyback Yield %

For the Biotechnology subindustry, Cytophage Technologies's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytophage Technologies's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Buyback Yield % falls into.


;
;

Cytophage Technologies Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Cytophage Technologies's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0
=N/A%

Cytophage Technologies's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1.457) / 0
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Cytophage Technologies Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytophage Technologies Business Description

Traded in Other Exchanges
Address
26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4
Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

Cytophage Technologies Headlines